HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 3, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company committed to the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, announced today that company Chief Medical
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 8, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will
Phase 2b Trial Showed Positive Results In Slowing Cognitive Decline HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 7, 2016-- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 2, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that company Chief Medical Officer
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Company Releases Q2 Earnings Results and Details Upcoming Program Milestones HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 16, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq:VTVT), a clinical-stage biopharmaceutical company
Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated treatment regimen HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 10, 2016-- Please replace the release with the following corrected version due to multiple revisions.
Analysis shows azeliragon 5mg/day resulted in steadily increasing delay in time to cognitive deterioration in mild Alzheimer’s disease patients Azeliragon designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation TORONTO --(BUSINESS WIRE)--Jul.
Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation – three of the principal causes of neuronal damage in AD HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 14, 2016-- vTv Therapeutics Inc.
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will
Data show TTP399 improves glycemic control and insulin resistance without hypoglycemia NEW ORLEANS --(BUSINESS WIRE)--Jun. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for